CAR T-cell therapy tricks cancer cells with decoy, increases treatment efficiency in B-cell acute lymphoblastic leukemia
B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most ...
Targeted Oncology6h
Jurczak on BTK Inhibitors and the Future of B-Cell Lymphoma Therapy
Wojciech Jurczak, MD, PhD, ​​discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase ...
Targeted Oncology5h
FDA Grants Azer-Cel Fast Track Status in DLBCL
Azercabtagene zapreleucel has been granted fast track designation from the FDA for the treatment of diffuse large B-cell ...
News Medical on MSN35m
Researchers develop TIM-3 decoy to enhance CAR-T therapy effectiveness for B-ALL tumors
B-cell Acute Lymphoblastic Leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common childhood cancer, making up 35% of pediatric cancer cases, but it ...
Halting the march of 'zombie cells': Platform paves the way for new treatments against age-related diseases
Halting the relentless march of so-called 'zombie cells' that drive aging and age-related diseases could be a step closer ...
Ophthalmology Times11h
Unity Biotechnology releases topline results from phase 2b ASPIRE trial of UBX1325 in patients with diabetic macular edema
UBX1325 is a novel BCL-xL inhibitor designed to eliminate senescent cells in diabetic retinal blood vessels, while leaving ...